 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...129130131132133134135136137138139...143144» |
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: EMR 62241-056: Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) (clinicaltrials.gov) - Mar 9, 2014
P2, N=33, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Combination therapy, Metastases: A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis (clinicaltrials.gov) - Mar 6, 2014
P2, N=8, Terminated, Sponsor: Austrian Breast & Colorectal Cancer Study Group
Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Metastases: Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer (clinicaltrials.gov) - Mar 3, 2014
P2, N=7, Terminated, Sponsor: Louisiana State University Health Sciences Center Shreveport
ABCSG guaranteed completed treatment period for ethical reasons. Active, not recruiting --> Terminated; Principle Investigator left the institution.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer (clinicaltrials.gov) - Mar 3, 2014
P2, N=7, Terminated, Sponsor: Louisiana State University Health Sciences Center Shreveport
Active, not recruiting --> Terminated; Principle Investigator left the institution. N=41 --> 7
- |||| Imprime PGG (odetiglucan) / HiberCell
Trial completion, Combination therapy, Metastases: Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Mar 2, 2014
P2, N=90, Completed, Sponsor: Biothera
N=41 --> 7 Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: FOCULM: FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 26, 2014
P2, N=106, Recruiting, Sponsor: Sun Yat-sen University
Active, not recruiting --> Completed N=60 --> 106
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: FOCULM: FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 25, 2014
P2, N=106, Recruiting, Sponsor: Sun Yat-sen University
N=60 --> 106 Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer (clinicaltrials.gov) - Feb 23, 2014
P2, N=54, Recruiting, Sponsor: Tianshu Liu
- | Erbitux (cetuximab) / Eli Lilly
Trial completion, Metastases: Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=62, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Trial completion, Monotherapy, Metastases: Cetuximab in Treating Patients With Recurrent or Progressive Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: Jonsson Comprehensive Cancer Center
Active, not recruiting --> Completed Recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Radiation Plus Cetuximab in Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Feb 22, 2014
P2, N=30, Completed, Sponsor: University of Heidelberg
Recruiting --> Completed Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, IO biomarker, Metastases: Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Feb 22, 2014
P2, N=165, Completed, Sponsor: ImClone LLC
Active, not recruiting --> Completed No longer recruiting --> Completed
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Feb 22, 2014
P2, N=57, Completed, Sponsor: ImClone LLC
No longer recruiting --> Completed No longer recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy: Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: Gynecologic Oncology Group
No longer recruiting --> Completed Active, not recruiting --> Completed
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy (clinicaltrials.gov) - Feb 22, 2014
P2, N=87, Completed, Sponsor: ImClone LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer (clinicaltrials.gov) - Feb 22, 2014
P3, N=0, Completed, Sponsor: NCIC Clinical Trials Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, IO biomarker, Metastases: Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=39, Completed, Sponsor: ImClone LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=66, Completed, Sponsor: ImClone LLC
Active, not recruiting --> Completed No longer recruiting --> Completed
- ||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer (clinicaltrials.gov) - Feb 22, 2014
P3, N=1302, Completed, Sponsor: ImClone LLC
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer (clinicaltrials.gov) - Feb 22, 2014
P3, N=102, Completed, Sponsor: ImClone LLC
No longer recruiting --> Completed No longer recruiting --> Completed
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=744, Completed, Sponsor: ImClone LLC
No longer recruiting --> Completed Active, not recruiting --> Completed
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma (clinicaltrials.gov) - Feb 22, 2014
P2, N=250, Completed, Sponsor: ImClone LLC
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=32, Completed, Sponsor: ImClone LLC
No longer recruiting --> Completed No longer recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Feb 20, 2014
P2, N=128, Recruiting, Sponsor: M.D. Anderson Cancer Center
No longer recruiting --> Completed Active, not recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Cetuximab in Treating Patients With Stage IV Colorectal Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Cetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Stage III or Stage IV Head and Neck Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Jonsson Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer (clinicaltrials.gov) - Feb 19, 2014
P3, N=0, Completed, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed No longer recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date: Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors (clinicaltrials.gov) - Feb 19, 2014
P2, N=60, Recruiting, Sponsor: Cliniques universitaires Saint-Luc- Universit
No longer recruiting --> Completed Initiation date: May 2013 --> Jan 2014
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open: Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors (clinicaltrials.gov) - Feb 19, 2014
P2, N=60, Recruiting, Sponsor: Cliniques universitaires Saint-Luc- Universit
Initiation date: May 2013 --> Jan 2014 Not yet recruiting --> Recruiting
- ||| Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: Neo-Adjuvant Study in Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Feb 17, 2014
P2, N=116, Active, not recruiting, Sponsor: The Methodist Hospital System
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer (clinicaltrials.gov) - Feb 12, 2014
P1, N=17, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=24 --> 17
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: FOCULM: FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 12, 2014
P2, N=106, Recruiting, Sponsor: Sun Yat-sen University
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer (clinicaltrials.gov) - Feb 12, 2014
P1, N=17, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=24 --> 17 Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver (clinicaltrials.gov) - Feb 11, 2014
P1, N=140, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Feb 9, 2014
P1/2, N=43, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=55 --> 43
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Metastases: Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx (clinicaltrials.gov) - Feb 4, 2014
P3, N=32, Terminated, Sponsor: University of Alabama at Birmingham
N=55 --> 43 Active, not recruiting --> Terminated
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial: SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN (clinicaltrials.gov) - Feb 4, 2014
P2, N=92, Recruiting, Sponsor: University of Pittsburgh
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Retrospective data, Review, Metastases: EMR062202-546: A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice (clinicaltrials.gov) - Feb 2, 2014
P=N/A, N=60, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Terminated Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1/2 trial, Metastases: COMMENCE: A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck (clinicaltrials.gov) - Feb 2, 2014
P1/2, N=120, Not yet recruiting, Sponsor: Radboud University
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: MUTEX: Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable Fc?RIIa (CD32) Genotype (clinicaltrials.gov) - Feb 2, 2014
P2, N=72, Active, not recruiting, Sponsor: Merck KGaA
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- saridegib oral (IPI 926 oral) / Infinity Pharma, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change: Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer (clinicaltrials.gov) - Jan 28, 2014
P1, N=9, Completed, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting N=24 --> 9
- saridegib oral (IPI 926 oral) / Infinity Pharma, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer (clinicaltrials.gov) - Jan 28, 2014
P1, N=9, Completed, Sponsor: University of Colorado, Denver
N=24 --> 9 Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: DeLOS II: Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA) (clinicaltrials.gov) - Jan 22, 2014
P2, N=170, Active, not recruiting, Sponsor: ClinAssess
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Cetuximab and Lenalidomide in Head and Neck (clinicaltrials.gov) - Jan 22, 2014
P2, N=40, Completed, Sponsor: University of Chicago
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Surgery, Post-surgery: ACCRA-HN: Adjuvant Cetuximab and Chemoradiation in Head and Neck Cancer (clinicaltrials.gov) - Jan 21, 2014
P2, N=80, Completed, Sponsor: Heinrich-Heine University, Duesseldorf
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies (clinicaltrials.gov) - Jan 20, 2014
P1, N=31, Completed, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| imgatuzumab (RO5083945) / Centessa
Trial completion, Combination therapy, Metastases: A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 19, 2014
P2, N=169, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed